Format

Send to

Choose Destination
Int J Psychiatry Med. 2019 Mar;54(2):150-156. doi: 10.1177/0091217418791455. Epub 2018 Jul 30.

Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report.

Author information

1
1 Department of Psychiatry and Psychotherapy, Psychiatric Services Aargau AG, Brugg, Switzerland.
2
2 Department for Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Zurich, Switzerland.

Abstract

OBJECTIVES:

Anecdotal reports and preliminary studies suggest a therapeutic potential of cannabis in Tourette syndrome. We report the case of a female patient suffering from treatment-resistant Tourette syndrome.

METHODS:

Guideline-directed antipsychotic treatment with risperidone and aripiprazole as well as pure delta-9-tetrahydrocannabinol had no significant effect on Tourette syndrome symptomatology.

RESULTS:

Following administration of a daily dosage of 10 mg delta-9-tetrahydrocannabinol combined with 20 mg cannabidiol (CBD), the patient showed a rapid and highly significant improvement in the Yale Global Tic Severity Scale.

CONCLUSIONS:

It can be speculated whether the beneficial effects may rely on the pharmacological properties of cannabidiol.

KEYWORDS:

Tourette syndrome; cannabidiol; cannabis; delta-9-tetrahydrocannabinol; tic disorders

PMID:
30058466
DOI:
10.1177/0091217418791455
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center